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Mitochondrial uncoupling proteins regulate
angiotensin-converting enzyme expression: crosstalk
between cellular and endocrine metabolic regulators
suggested by RNA interference and genetic studies
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Uncoupling proteins (UCPs) regulate mitochondrial function,
and thus cellular metabolism. Angiotensin-converting en-
zyme (ACE) is the central component of endocrine and local
tissue renin–angiotensin systems (RAS), which also regulate
diverse aspects of whole-body metabolism and mitochon-
drial function (partly through altering mitochondrial UCP
expression). We show that ACE expression also appears to
be regulated by mitochondrial UCPs. In genetic analysis of
two unrelated populations (healthy young UK men and
Scandinavian diabetic patients) serum ACE (sACE) activity
was significantly higher amongst UCP3-55C (rather than T)
and UCP2 I (rather than D) allele carriers. RNA interference
against UCP2 in human umbilical vein endothelial cells
reduced UCP2 mRNA sixfold (P< 0·01) whilst increasing
ACE expression within a physiological range (<1·8-fold at
48 h; P< 0·01). Our findings suggest novel hypotheses.
Firstly, cellular feedback regulation may occur between
UCPs and ACE. Secondly, cellular UCP regulation of sACE
suggests a novel means of crosstalk between (and mutual
regulation of) cellular and endocrine metabolism. This might
partly explain the reduced risk of developing diabetes and
metabolic syndrome with RAS antagonists and offer insight
into the origins of cardiovascular disease in which UCPs
and ACE both play a role.
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Introduction
Both circulating and local (tissue/cellular) renin–angiotensin
systems exist
As a pivotal component of the endocrine renin–angiotensin
systems (RAS), angiotensin-converting enzyme (ACE) plays
an important role in the regulation of the human circulation.
Cleaved from an anchoring stalk on endothelial cells that line
blood vessels, it is released into the circulation, acting upon
the protein angiotensin I to yield eight amino-acid angioten-
sin II (Ang II). Ang II provokes release of the hormone aldo-
sterone from the adrenal glands, which leads to salt and
water retention by the kidney. It also causes constriction of
small blood vessels in the arterial tree – actions which, to-
gether, serve to elevate blood pressure. In medical care,
RAS antagonists, whether ACE inhibitors (ACEIs) or drugs
antagonising the actions of Ang II at its type 1 receptor
(AT1R blockers or ARBs), are widely used in the treatment of
elevated blood pressure, or in the treatment of heart failure
in which reduced vascular tone and reduced circulating vol-
ume may offer advantages.
But the RAS has functions far beyond this, being found in
cells and tissues throughout the body. Here, Ang II action on
cell surface AT1R and type 2 (AT2R) receptors affects the func-
tion of the cell that synthesised it (autocrine actions), or the
function of nearby cells (paracrine actions). Ang II can also
act as an intracellular signalling molecule (so-called intracrine
action): some cells internalise Ang II made elsewhere, and
others synthesise it de novo (reviewed in [1]). In this way, both
circulating and tissue RAS can act independently or interact in
the regulation of cell function.
ACE activity is influenced by naturally occurring variation
in the ACE gene
Circulating and tissue ACE activity varies greatly between
individuals, and common genetic variation in the ACE gene
explains up to 40% of such differences. In particular, each of
the two inherited ACE genes can exist in one of two forms.
One form contains a small extra sequence of DNA (287 base
pairs) and is known as the ‘insertion’ or ‘I’ variant (allele). If this
fragment is missing, the gene variant is known as the deletion,
or ‘D’, allele. In both the circulating/endocrine [2] and cellular
[3] RAS, the ‘I’ allele is associated with lower ACE activity.
RAS play an important role in regulating metabolism in
health and disease
One important function of local and endocrine RAS is in the
regulation of cellular and whole-body metabolism. This they
do in numerous ways, inﬂuencing, for example, the storage
and release of fatty acid fuels from fat cells (adipocytes)
[4]; regulating islet cells in the pancreas, which are responsi-
ble for releasing the hormone insulin and thus regulating up-
take and use of glucose [5]; and regulating the uptake and
use of carbohydrate fuel by the liver [6]. But Ang II inﬂuences
more than the uptake of metabolic substrates. It increases
liver, skeletal muscle and whole-body oxygen consumption
in rodents [7–9]. Conversely, ARBs and ACEI reduce oxygen
consumption related to renal sodium transport [10]. Human
data are supportive of such metabolic roles: the ACE I allele
is associated not only with lower circulating and tissue ACE
activity but also with successful physical performance in hyp-
oxic environments [11–14] and with enhanced training-related
falls in skeletal muscle oxygen consumption per unit of
external work [15,16].
These metabolic roles of RAS appear to inﬂuence the devel-
opment of disease in humans. Genetically determined high
ACE activity (marked by the ACE D rather than I allele) is associ-
ated with the development of metabolic syndrome (hyperten-
sion, diabetes and abnormal blood lipid proﬁle) [17], whilst
reducing RAS activity (by the use ACEIs or ARBs) also reduces
the risk of people developing diabetes [18], or of them suffering
a myocardial infarction (heart attack), clinical signs or symp-
toms of heart failure, stroke or death from a cardiovascular
cause [19].
Ang II has direct effects on mitochondria
The cellular metabolic effects of RAS may be mediated, in part,
by direct action of Ang II on the mitochondrial respiratory
chain (reviewed in [20]). Mitochondria are the intracellular
organelles responsible for generating the body’s energy
currency, adenosine triphosphate (ATP). The respiratory or
electron transport chain of the inner mitochondrial membrane
consists of an assembly of several discrete electron carriers,
which are grouped into complexes. Three of these complexes
(complexes I, III and IV) work as oxidation–reduction-driven
proton pumps: electrons derived from diverse metabolic
substrates combine with molecular oxygen to form water,
and the energy released drives the translocation of protons
(hydrogen ions, H+) from the mitochondrial matrix, across the
otherwise impermeable inner membrane, and into the inter-
membrane space. This results in a chemiosmotic gradient
(a mitochondrial membrane potential) across the inner mem-
brane, which drives the ﬂow of these protons back into the
matrix through ATP synthase, which produces ATP from aden-
osine diphosphate (ADP) and inorganic phosphate. When the
membrane potential is high (for instance at rest when no use-
ful work is being performed and the demand for ATP is low),
complexes I and III are also able to produce reactive oxygen
species (ROS), where diatomic oxygen (O2) combines with a
single electron only to form superoxide rather than being fully
reduced to water. These ROS can cause substantial cell
damage [21]. Exogenously administered Ang II trafﬁcs to mito-
chondria [22,23], where outer mitochondrial membranes may
express AT1Rs [24]. Ang II will then stimulate production of
ROS, NADPH oxidase-dependent superoxide and ADP-
independent respiration – which reduces the activities of com-
plexes I and III. Mitochondria may have the capacity to endog-
enously synthesise Ang II [25–29].
Uncoupling proteins can ‘short circuit’ the mitochondrial
membrane and reduce the membrane potential
The ‘coupling’, which connects substrate energy with the
derived ATP is, however, incomplete – protons can ﬂow back
into the matrix in a manner disconnected from ATP synthesis.
This is in part controlled by nuclear-encoded, mitochondrial-
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targeted uncoupling proteins (UCPs), of which ﬁve mammalian
forms are recognised [30]. Of these, UCP4 and UCP5 are
principally neuronally expressed [31]. The remaining three
(UCP1–3) have close sequence homology. Expression of UCP2
is recognised in tissues including white adipose tissue, liver,
and cardiac and skeletal muscle, whilst that of UCP1 is limited
to brown adipose tissue (BAT), and of UCP3 largely to BAT and
skeletal and, to a lesser extent, cardiac muscle [32]. By
allowing protons to ﬂow back across the inner mitochondrial
membrane without coupled ATP synthesis, UCPs reduce the
membrane potential and help protect the cell from the genera-
tion of excessive ROS from complexes I and III [33,34]. Thus,
expression of UCP2 is increased as ROS levels rise, in a nega-
tive feedback regulatory system [35]. Indeed, it has been
hypothesised that UCPs evolved in response to severe ROS
formation resulting from the beta-oxidation of fat [36].
UCPs alter metabolism through mechanisms in addition
to altering mitochondrial membrane potential
This said, UCP2 may have metabolic roles other than, or
beyond those related to, proton gradient and ROS generation
(well reviewed in detail in [37]). Indeed, it appears to increase
fatty acid oxidation [38], whilst long-chain fatty acid intake is
also known to induce UCP2 expression [39]. Further, UCP2
appears to play roles in the regulation of food intake [14,15]
and insulin secretion [16,17], although the mechanisms by
which such actions occur remain poorly understood [40].
One means by which to explore the physiological roles of
UCPs is through the study of genetic variants that are associ-
ated with differences in their expression. Helpfully, even a
common genetic variation in the UCP3/2 locus inﬂuences UCP
expression.
Functional variation exists in the genes that encode the
UCPs
A common variant exists in the UCP2 gene’s promoter region
(the area that initiates gene transcription), comprising the
presence of an adenine base (rather than the more frequent
guanidine: UCP2-866G>A, rs659366). This variant lies in a
region containing binding sites for transcription factors (fac-
tors that stimulate gene transcription) inﬂuenced by hypoxia
and inﬂammation. Linkage disequilibrium (LD) refers to the
ﬁnding that some gene variants are not randomly distributed
in a population: being in proximity, they tend to ‘travel to-
gether’. This is the case for this UCP2 variant (Fig. 1), which
is in complete LD with a second promoter variant
(2723T>A). These also explain 71% of the variation in mes-
senger RNA (mRNA) transcript ratio associated with the
deletion/insertion (D/I) of 45 base pairs of DNA (in exon 8
of the gene) [41]. The UCP2-866A allele is associated with
lower gene transcription (repression) in somatic non-β cells
[42] but more effective UCP2 gene transcription in pancreatic
β cells (those that make insulin). In humans, the UCP2-866A
allele is thus associated with reduced insulin sensitivity [42]
and glucose-stimulated insulin secretion [43], diabetes in
obese subjects [42], oxidative stress in diabetic people [44]
and future cardiovascular risk in diabetic and non-diabetic
people [44]. The UCP2 I allele is associated with reduced
UCP2 mRNA stability [41], and with elevated body mass index
[45] and variably with basal metabolic rate [46].
Figure 1. Diagrammatic representation of the human UCP3 and UCP2 gene locus (chromosome 11q13) with the relative positions and link-
age disequilibria (LD) of the three common genetic variants in this study: the UCP3-55C>T promoter variant, UCP2-866G>A promoter variant
and the UCP2 D/I variant. UCP2 is approximately 7 kb downstream from UCP3. They share 72% sequence homology. The exonic structures
are shown (rectangles) as well as the transcription start points (angled arrows), translation start codons (ATG) and translation stop codons
(TGA). UCP3 has two translation stop codons, yielding either a short (TGAS) or long (TGAL) transcript. The short transcript does not code
for a functioning protein. There are three ATG codons at positions 888, 924 and 948 within an open reading frame in exon 2 of UCP2, which
could initiate translation of a putative short protein (depicted as ATGS). However, translation only starts at the ATG codon in exon 3 to yield
UCP2 protein [47]. LD (or D′) is the non-random association of alleles or genetic markers in a population and is measured between 0 and 1.
When two alleles are completely randomly associated, D′ is zero. When two alleles are completely linked or associated, then D′ = 1. In the
figure, D′ is shown between the three gene variants for the HMAR (§) and T1DM (†) studies. In both studies, there was significant LD
between the UCP2-866G>A and UCP2 D/I variants (D′ 0·38 – 0·54; P< 0·0001) and negative LD (0·31 to 0·26; P = 0·0005) between
the UCP3-55C>T and UCP2 D/I variants, but no LD between the UCP3-55C>T and UCP2-866G>A variants. The common UCP3-55C allele
therefore showed significant allelic association with the rare UCP2 I allele, and the latter with the rare UCP2-866A allele.
■ Primary Research S. S. Dhamrait et al.
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Meanwhile, a common variant in the regulatory ‘promoter’
region of the UCP3 gene (the presence of a thymidine base
rather than the more frequent cytosine: 55C>T, rs1800849)
is in negative LD with the UCP2 D/I polymorphism [48], the T
allele being associated with obesity in a recessive manner
[48] and with higher circulating low-density lipoproteins
cholesterol levels [49]. For clarity, such LD is demonstrated in
Fig. 1, which relates to our study populations described later.
We have recently shown the combined presence of both the
UCP3-55C allele and the UCP2-866A allele (the ‘UCP3-55C/
UCP2-866A haplotype’) to be associated with gains in muscle
performance following endurance training [50] in a similar
pattern to that previously associated with the ACE I allele
(lower ACE activity) [51].
ACEmay regulate UCP expression. But do UCPs regulate
ACE expression?
Some of the metabolic effects associated with ACE and Ang II
(refer to the previous discussion) are now thought to be medi-
ated through regulation of UCP expression: Ang II upregulates
expression of UCP1 [52], UCP2 [53] and UCP3 [54]. However,
an unexpected (and completely novel) ﬁnding made by our
group suggested an inverse relationship: that UCP activity
might also regulate ACE expression. We had previously re-
ported a correlation between lower serum ACE (sACE) activity
and decreased risk of hypoglycaemia in Danish diabetic adult,
going on to show a similar association of the ACE I allele (i.e.
genetically determined low sACE) with a lower risk of severe
hypoglycaemia [55]. Low ACE activity is favourable for perfor-
mance and hypoglycaemia awareness when substrate avail-
ability is limited, for example, during hypoglycaemia. As part
of our ongoing work, we recently genotyped these subjects
for the UCP3-55C>T polymorphism, ﬁnding an association
between UCP3 genotype and sACE activity. Such data suggest
a role for UCPs in the regulation of ACE activity, rather than
the (previously recognised) converse observation.
We sought to conﬁrm the validity of the ﬁnding by
performing more detailed genetic analysis in this sample of
210 type 1 diabetic study patients (≥18 years old; 117 women;
mean age 45·5 ± 13·7 years; none taking RAS antagonists): the
T1DM study. We then sought replication of our ﬁndings in a sec-
ond completely independent dataset, comprising 250 Caucasian
British healthy male army recruits (mean age 19·4±2·2 years):
the HMAR study.
Finally, as sACE is derived from endothelial cells, we per-
formed in vitro experimentation to conﬁrm the co-expression
of both ACE and UCP2 mRNA in human umbilical vein endothe-
lial cells (HUVECs) before determining whether changes in UCP
expression (by RNA interference) could directly alter endothe-
lial ACE expression.
Results
Gene variants in the adjacent UCP2 and UCP3 loci are
tightly associated
Genotype distributions (Table 1) were in Hardy–Weinberg equilib-
rium (meaning that they are consistent with stability over gener-
ations) and similar to those previously reported in Caucasians
[41,45,48]. There was signiﬁcant LD between the UCP2-866G>A
and UCP2 D/I variants (D 0·38–0·54; P< 0·0001; Fig. 1) and
negative LD (0·31 to 0·26; P=0·0005) between the UCP3-
55C>T and UCP2 D/I variants, as previously described in a South
Indian cohort [48], but no LD between the UCP3-55C>T and
UCP2-866G>A variants. The UCP3-55C allele therefore showed
allelic association with the rare UCP2 I allele, and the latter with
the UCP2-866A allele. There was no association between any
genotype and common descriptive population variables.
sACEactivity is strongly associatedwithUCP2/3 genotype
sACE activity was normally distributed in both studies and
weakly correlated with age (HMAR r=0·19; P=0·02, T1DM
r=0·12; P=0·04) but no other population variables. Age-
adjusted sACE was therefore used in subsequent analyses. As
expected, sACE activity was higher in T1DM subjects, with
levels similar to those of previously published data [56]. The
wide distribution of ACE activities in the T1DM group may partly
reﬂect differences in diabetic phenotype, such as the presence
or absence of nephropathy [56].
In both studies, sACE activity differed by UCP genotype.
For UCP2, the I allele was associated with signiﬁcantly higher
sACE activity in both the HMAR study (25·8 ± 8·3 vs. 29·2
± 10·3 vs. 29·9 ± 7·3 nmol his-leu/ml/min for DD vs. DI vs. II,
linear trend P=0·04; I allele vs. DD homozygotes P=0·02)
and T1DM study (49·9 ± 15·5 vs. 50·5 ± 17·6 vs. 60·4
± 24·2 nmol his-leu/ml/min; P=0·04 analysis of variance
[ANOVA]). Considering UCP3, the ACE activity for CC versus
Table 1. UCP3-55C>T, UCP2-866G>A and UCP2 D/I genotype distributions and rare allele frequencies (with 95% confidence
intervals in parentheses) in the HMAR and T1DM studies
Study
Gene variant
UCP3-55C>T UCP2-866G>A UCP2 D/I
HMAR 128/71/13 82/108/22 104/92/16
0.229 (0.189–0.269) 0.358 (0.313–0.404) 0.292 (0.249–0.336)
T1DM 116/78/16 84/98/28 116/76/18
0.262 (0.220–0.304) 0.367 (0.321–0.413) 0.267 (0.224–0.309)
P HMAR vs. T1DM 0.53 0.97 0.74
There was no significant difference in genotype distribution between the two studies.
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CT versus TT genotypes was 53·0 ± 17·0 versus 49·5 ± 18·3 ver-
sus 45·5 ± 16·6 nmol his-leu/ml/min (P=0·02 ANOVA) in the
T1DM cohort. In the HMAR group, ACE activity was 28·1 ± 9·6 ver-
sus 27·7 ± 8·4 versus 22·8 ± 8·7 nmol his-leu/ml/min (P=0·07
ANOVA), with sACE activity lower amongst UCP3TT homozygotes
in both cohorts (by, on average, 6–8nmol his-leu/ml/min;
Fig. 2), a ﬁnding conﬁrmed on repeated measures analysis in
the HMAR study (P=0·03). In multivariate analysis, the statistical
interaction between the three UCP genotypes accounted for up to
4·1% and 5% of the inter-individual variation in sACE activity in
the HMAR and T1DM studies, respectively, but with the majority
of this variation accounted for by the statistical interaction
between UCP2-866G>A and UCP2D/I genotypes (P=0·001).
The expected sACE activity phenotypic means according to
estimated haplotypes (groupings of the different gene variants,
found in combination) for study subjects in the HMAR and
T1DM studies are depicted in Fig. 3. Uncommon haplotype
groups with a frequency <0.05 in both studies were excluded
from subsequent analysis (i.e. the UCP3-55T/UCP2-866A/
UCP2I and the UCP3-55T/UCP2-866G/UCP2I haplotypes). There
was insufﬁcient statistical power to detect a haplotypic effect
in predicting sACE activity in the HMAR study (P=0·24), per-
haps contributed to by the limited number in such haplotype
groups and compounded by the different distribution on ACE
activity observed in this group when compared with T1DM
subjects (see section on Discussion). However, there was a sig-
niﬁcant haplotype effect in predicting sACE activity in the T1DM
subjects (P=0·01). The lowest sACE activity was seen amongst
individuals with the UCP3/2 haplotype CAD in both studies. A
single nucleotide polymorphism (SNP) change from the UCP3/
2 CAD to CAI haplotype led to a signiﬁcant mean increase in
sACE activity of 10·0 nmol his-leu/ml/min in the T1DM study
(P=0·008). The UCP2 I allele has been associated with de-
creased mRNA stability, with expression dependent on varia-
tion in the UCP2G>A polymorphism [41]. Thus, genotypes
associated with putative lower UCP2 expression were associ-
ated with higher sACE activity.
The association of UCP2/3 genotype with sACE activity
might in part be mediated through UCP’s regulation of
ACE expression
In theory, differences in UCP expression may drive systemic
(whole body) physiological effects (such as changes in insulin
secretion, or in inﬂammatory or immune responses), which
might change sACE activity in ways yet unknown. Alternatively,
changes in cellular UCP expression might more directly inﬂu-
ence ACE expression in those same cells. We sought to clarify
the latter hypothesis through in vitro experimentation. Speciﬁ-
cally, we sought to determine whether cellular ACE gene ex-
pression (ACE mRNA levels) would alter when UCP expression
(UCP mRNA activity) was reduced by introducing targeted
‘small interfering RNA’ molecules (siRNA). We performed this
experiment in HUVECs, given that circulating ACE is derived
from such vascular endothelial cells.
Firstly, the mRNA co-expression of ACE, UCP2, UCP3 and
GAPDH (a housekeeping gene) in HUVECs was conﬁrmed using
a two-step reverse transcription polymerase chain reaction am-
pliﬁcation (RT-PCR). Both UCP2 and ACEmRNA were found to be
expressed abundantly in cultured HUVECs, whilst expression of
UCP3 was conﬁrmed at a lower level (Fig. 4).
Subsequent quantitative PCR conﬁrmed that UCP2 mRNA
expression was reduced at all time points (between threefold
and sixfold, P< 0·0001, Fig. 5) in endothelial cells
transfected with two different siRNAs against UCP2 (siRNA1
and siRNA2), when compared with scrambled siRNA (a nega-
tive control, not speciﬁcally targeted at UCP2). In keeping
with data from our genetic study, this effect was associated
with a signiﬁcant increase in ACE expression, ACE mRNA ris-
ing at 30 and 48h (1·2- to 1·4-fold and approximately 1·8-
fold, respectively, P<0·001).
A)
B)
Figure 2. Mean age-adjusted serum ACE (sACE) activity by
UCP3-55C>T, UCP2-866G>A and UCP2 D/I genotypes in A: healthy
male army recruits (HMAR) study and B: type 1 diabetic people
(T1DM) study. Data are mean ± SD. The number of individuals in
each genotype group is given at the top of each bar. The P value for
the statistical comparison of mean age-adjusted sACE activity
between genotypes is shown above each gene variant. There were
significant differences in sACE activity by UCP2D/I genotype in
both studies and by UCP3-55C>T genotypes in the T1DM study.
NS = non-significant.
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Discussion
Genetic variation in the UCP3/2 locus is associated with
sACE activity
Ours is the ﬁrst study to demonstrate an association of sACE
with a genetic variant outside the ACE gene itself [57–59]. We
showed that the UCP3-55C (rather than T) and UCP2 I (rather
than D) alleles were associated with higher age-adjusted sACE
activity, the interaction between the three genotypes account-
ing for 4·1% and 5%, respectively, of the inter-individual
variation in age-adjusted sACE activity in two independent
genotyping studies – one of healthy young UK Caucasian men
and one of Scandinavian middle-aged diabetic people. The low-
est sACE was associated with UCP3-55C/UCP2-866A/UCP2D
(UCP3/2 CAD) haplotype in both studies, an SNP change from
UCP3/2 CAD to CAI increasing sACE by 10·0 nmol his-leu/ml/
min in the T1DM. We are unable to conﬁdently attribute the ob-
served effects to a precise allele, given that the UCP3-55C allele
showed allelic association with the rare UCP2 I allele, and the
latter with the UCP2-866A allele. Even the haplotypes described
may simply mark functional variation elsewhere in the cluster.
The use of exome sequencing in substantially expanded
cohorts is thus suggested.
The replication of the association of UCP genotype with sACE
activity in two independent and diverse groups strengthens
conﬁdence in the validity of the ﬁndings. It is worthy to note
that ACE activity was substantially higher in the T1DM group
than in HMAR group – a ﬁnding unlikely related to the use of
two different methodologies of ACE assay. Indeed, an
established literature shows ACE activity (when assayed using
the same commercial Sigma assay we used) to be elevated in
diabetic people to levels commensurate with those we identi-
ﬁed and with similar levels in controls to those we report [56].
A)
B)
Figure 3. A: The UCP3-55C>T, UCP2-866G>A and UCP2D/I haplotype frequencies are shown in descending order of frequency for both the
HMAR and T1DM studies. The most common haplotype is the UCP3-55C/UCP2-866G/UCP2D (CGD) allele. Subsequent analysis was
confined to common haplotypes with a frequency greater than 0.05. B: Predicted UCP3-55C>T, UCP2-866G>A and UCP2D/I haplotype
effects on age-adjusted serum ACE (sACE) activity in the HMAR and T1DM study subjects. Data are mean ± SD for each single allele effect.
Haplotypes with a frequency less than 0.05 are not represented in the figure because of the very small group size and resulting wide standard
deviation for sACE activity. §There was a significant haplotype effect in predicting sACE activity overall in the T1DM subjects (P = 0·01), but
not in the HMAR study. *The bracket shows the comparison in the T1DM study between those individuals with the CAD haplotype who had
the lowest mean sACE activity and those with the CAI haplotype who had the highest mean sACE activity. A SNP change from the UCP3/2
CAD to CAI haplotype led to a significant mean increase in sACE activity of 10·0 nmol his-leu/ml/min in the T1DM study (P = 0·008). Indi-
viduals with the CAD haplotype in the HMAR study also had the lowest sACE activity but are not shown owing to the low sample size.
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The use of two different methodologies relates to the different
geographical locations of sample acquisition and analysis.
Both techniques are considered reliable and are well validated.
A small systematic bias, related to the assay used, would not in
any way affect the ﬁndings or conclusions of our study.
UCP2 RNA interference increases ACEmRNA expression
Most importantly, however, our data suggest that this asso-
ciation may partly result from UCP2’s modulation of ACE
expression. We conﬁrmed the expression of UCP2 reported in
endothelial cells of diverse origin [60–63]. Those of the
vasculature are central to the pathophysiology of atherosclero-
sis. Indeed, UCP2 genotype is associated with the develop-
ment of vascular disease [44], whilst ACE inhibition appears
protective [64].
In HUVECs, a threefold to sixfold reduction in UCP2 mRNA
(induced by transfection with two separate and different
siRNA against UCP2) was reproducibly associated with an in-
crease in ACE mRNA expression (1·2–1·4-fold at 30 h, and a
near doubling at 48 h, P< 0·01) – the scale of altered ACE ex-
pression (1·2–1·8-fold) by UCP2 RNA interference being simi-
lar to that observed in the physiological context [65–68]. We
cannot discount an additional inﬂuence on ACE stalk cleav-
age, however, and would advocate further investigation of
this possibility.
Is there negative feedback between UCP2 and ACE at
the cellular level?
UCPs regulate mitochondrial metabolism. Mitochondrial regu-
lation by RAS [7,9,20,25,69] may partly be mediated through
modulation of UCP expression: Ang II upregulates expression
of tissue UCP1 in brown fat [52] and UCP2 expression in brain
[70], pancreatic beta-cells [53,71], and hepatic [72], renal [73]
and cardiac [74] tissue. ACE inhibition reduces UCP2 expres-
sion in adipose and cardiac tissue [68,75], whilst adipose
Figure 5. UCP2 RNA interference results in
a significant increase in ACE mRNA.
HUVECs were transfected with two different
siRNA against UCP2 (siRNA 1 and siRNA 2)
and total RNA isolated at 30 and 48 h.
Quantitative RT-PCR was performed on an
ABI prism 7900HT. UCP2 RNA interference
resulted in a significant decrease between
threefold and sixfold in UCP2 mRNA ex-
pression at 30 and 48 h associated with a
significant increase in ACE mRNA (1.2- to
1.4-fold at 30 h and 1.8-fold at 48 h). (Exper-
iments were repeated a minimum of five
times; data are mean ± SD.) †P< 0.0001.
*P< 0.001.
Figure 4. Agarose gel electrophore-
sis confirmed that UCP2, UCP3 and
ACE mRNA are co-expressed in en-
dothelial cells. Non-quantitative RT-
PCR for GAPDH, UCP2, ACE and
UCP3 was performed on mRNA iso-
lated from four separate cultures of
HUVECs grown to confluency, and
the products run on a 2% agarose
gel against a 1 kb DNA ladder. There
is less product in the last two lanes,
but this does not affect the result.
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UCP3 expression is reduced in AT2R knockout rodents [54].
However, Ang II’s inﬂuence on UCP expression may be both
tissue and context dependent, given the existence of
seemingly conﬂicting data: in other studies, Ang II action at
the AT1R reduces cardiac UCP2 and UCP3 expression [76];
adipose UCP1 expression is elevated in AT1R gene knockout
mice [77] and those treated with AT1R antagonists [78];
whilst ACE inhibition may have no effect on cardiac/skeletal
muscle UCP3 upregulation in response to thyroid hormones
[79] or may actually increase UCP2 expression in retinal
tissue [80].
Meanwhile, RAS inﬂuences whole-body metabolism in other
ways (e.g. through altered adipocyte function [4] and hepatic
metabolism [6]). Given this, our data suggest several hypothe-
ses. Firstly, ACE-UCPs feedback control may exist: this would
function by Ang II altering mitochondrial function through
changes in UCP expression, the latter feeding back to change
Ang II synthesis through regulation of ACE expression.
Secondly, UCPs might be considered to regulate mitochon-
drial metabolism through changes in coupling, but also
through independent mitochondrial effects of Ang II. Such hy-
potheses would be supported were UCP expression is shown
to regulate that of ACE in cells beyond those derived from
the endothelium.
The regulation of endocrine sACE by cellular UCPmay rep-
resent a novel interface between local cellular metabolism
and endocrine metabolic regulation
UCP2 negatively regulates both pancreatic β cell glucose-
stimulated insulin secretion [81] and central neuronal glucose
control of peripheral glucose utilisation [82]. Fatty acids in-
duce both the expression and activity of UCP2 in pancreatic
β cells [83,84], and superoxide activation of UCP2 is depen-
dent on the presence of fatty acids [35]. Skeletal muscle
UCP2 and UCP3 mRNA expression is induced by a high fat diet
[85], and plasma free fatty acid levels are positively correlated
with cardiac UCP2 protein levels [66]. Starvation leads to the
depletion of glycogen stores and an increased reliance on en-
ergy transduction from fatty acid oxidation. A similar period of
starvation reduces sACE activity [86] and also increases UCP
expression in skeletal muscle [65] – possibly as a protective
mechanism against oxidative stress [35]. Furthermore, lower
ACE activity in HUVECs promotes a survival advantage during
starvation [87]. Perhaps of greater relevance, RAS antagonists
prevent diabetes and improve insulin sensitivity (reviewed in
[18]), whilst the RAS appears to play a role in the pathogene-
sis of the ‘metabolic syndrome’ (hypertension/impaired glu-
cose tolerance/dyslipidaemia) [17,88,89]. Indeed, increased
RAS activity is common in obesity and is considered a possi-
ble link with associated diabetes and hypertension [89]. In
this regard, elevated RAS activity in adipocytes may play a
particular role [90], raising the prospect that the recognised
association between UCP2/3 genotype and obesity/diabetes
[41,42,45,46,49,91,92] might be partly adipose-RAS mediated.
This does not discount, of course, a role for elevated RAS
activity of endothelial (and UCP regulated) origin also playing
a role. However, we would advocate further experiments to
explore the inﬂuence of adipocyte UCP expression on that
of ACE.
Similarly, UCP3-55C/UCP2-866A haplotype is associated
with training-related gains in muscle performance [50], and it
is tempting to speculate that some of this effect might be ACE
mediated, given the existence of similar associations with
ACE genotype [51].
Future directions
Whilst conﬁdent in the validity of the observations we have
made, the implications remain speculative. Further studies
are also required to explore the means by which UCP might
alter ACE expression: is it direct or mediated, for instance, via
altered ROS activity? Inhibition of UCP2 or UCP3 could induce
ROS and thereby increase ACE activity. Might UCPs additionally
alter sACE activity through ACE stalk cleavage and thus
increase release into the circulation? In such regards, real-time
PCR analysis of the expression of other RAS components might
be performed in HUVECs, transfected in the manner that we
have described. RAS activity can prove protective to blood ves-
sels (especially, perhaps, through activation of AT2R rather
than AT1R) – and UCP’s role in regulating such vasoprotective
effects is worthy of exploration (given that reduced ROS activity
would also be vasoprotective). Recent data also suggest a role
for mitochondrial-associated membrane RAS in regulating
mitochondrial function – and the study of ACE activity in such
regions in response to altered UCP expression might also be
suggested. Exome sequencing may help identify the precise
functional UCP2/3 variant affecting sACE activity. Experimenta-
tion should also be extended to other cell types.
Materials and methods
Genetic studies
The association of UCP3/2 genotype with sACE activity was
explored in two distinct cohorts of European Caucasians:
young healthy British men and adult Danish patients with type
1 diabetes. Ethics committee approval was obtained, as was
written informed consent from all participants, with study pro-
tocols adhering to the Declaration of Helsinki (Defence Medical
Services Clinical Research Committee at the Army Training
Regiment, Bassingbourn, UK, and Hillerød Hospital, Hillerød,
Denmark).
Subjects
The HMAR study sample consisted of 250 consecutive healthy
male Caucasian British Army recruits (mean age 19·4±2·2years),
as previously described [93], 212 of whom had complete geno-
typic data.
The T1DM patients study comprised 262 consecutive Danish
adults (≥18 years old; 117 women; mean age 45·5 ± 13·7 years)
with a >2 year history of T1DM, as previously described [94].
Analysis was restricted to the 210 with complete genotype data
who were both ACEI and ARB naïve.
Genomic DNA was extracted from 10ml EDTA venous blood.
Serum was aspirated from centrifuged citrated blood and
stored at 20°C for subsequent blinded analysis of sACE.
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Measurement of sACE activity
For the HMAR study, sACE was assayed with a modiﬁed ﬂuo-
rometric method using carbobenzoxy-phenyl-alanyl-histidyl-
leucine (Z-phe-his-leu) as a substrate [95]. Interassay and
intraassay coefﬁcients of variation were 13% and 11%, respec-
tively. For the T1DM study, sACEwas assessed using a commercial
kinetic assay (Sigma Diagnostics, St Louis, MO, USA) based on
the hydrolysis of the synthetic tripeptide N-[3-(2-furyl)acrylolyl]-
l-phenylalanylglycylglycine to furylacryloylphenylalanine and
glycylglycine. ACE activity was determined by comparing sample
reaction rate with that derived from an ACE reference. The use
of two different methodologies relates to the different geographi-
cal locations of sample acquisition and analysis. The observed
difference in mean sACE activity between two studies does not
seem to be due to differences in the assays employed.
Genotyping
UCP3-55C>T, UCP2-866G>A and UCP2D/I genotypes were
determined by PCR ampliﬁcation using published primers and
conditions [41,45,48]. Products were resolved on a 7·5% poly-
acrylamide gel and conﬁrmed by two independent technicians
blind to all subject data, with discrepancies resolved by repeat
genotyping.
Influence of reducing UCP mRNA levels on cellular ACE
expression
HUVECs (European Collection of Cell Cultures, Salisbury, UK)
were cultured to 80% subconﬂuence before being cultured in
serum-free EGM™ for 48h to conﬂuence prior to all experiments.
siRNA transfection
Transfection was carried out according to the manufacturer’s
protocol. ACE (105310 and 103987) and UCP2 (120334 and
120336) siRNA as well as positive (GAPDH, 4390849) and neg-
ative (4611) controls were purchased from Ambion (Applied
Biosystems, Austin, TX, USA). siGLO Green control was pur-
chased from Dharmacon (Lafayette, CO, USA). Brieﬂy, cells
were cultured in six-well plates until conﬂuent. In optiMEM-1
(Invitrogen, Life Technologies Ltd, Paisley, UK), 200 nM siRNA
(with or without the same quantity of siGLO siRNA) was
diluted, with a ﬁnal volume of 180μl. Oligofectamine 10μl
(Invitrogen, Life Technologies Ltd, Paisley, UK) and 10μl
optiMEM-1 were premixed. Both mixtures were incubated for
10min, then mixed together, and incubated for a further
25min. The cells were washed with optiMEM-1 and covered
with 800μl fresh optiMEM. To each well, 200μl of prepared
mix siRNA+ oligofectamine was added dropwise. The cells
were incubated for 4 h at 36°C, after which a further 500μl
30% foetal calf serum/optiMEM-1 was added. Total RNAs were
extracted 24, 30 and 48h after transfection.
RNA extraction, reverse transcription and RT-PCR
Cellular RNA was isolated using the RNeasy® Mini Kit (Qiagen,
Crawley, UK) spin protocol. The RNA was stored at 80°C and
quantiﬁed using a nanodrop spectrophotometer (ND-8000,
Labtech, East Sussex, UK) prior to reverse transcription. Resul-
tant complementary DNA samples were stored at 20°C.
Human ACE, UCP2, UCP3 and GAPDH (housekeeping gene)
target sequences were ampliﬁed using forward and reverse
primers (Table 2) by PCR to conﬁrm co-expression. Ampliﬁca-
tion products were separated by electrophoresis on a 2%
agarose gel against a 1 kb DNA ladder.
RNA was extracted at 24, 30 and 48 h after HUVECs were
transfected with two different siRNAs against UCP2 (siRNA1
and siRNA2). Quantitative RT-PCR was performed on ABI prism
7900HT. Assays Hs00174179_m1, Hs00163349_m1 and
Hs01106052_m1 were used in combination to TaqMan gene
expression master mix to amplify ACE, UCP2 and UCP3 mRNA,
respectively. Three housekeeping genes were used: UBC
(Hs00824723_m1), β actin (Hs99999903_m1) and GAPDH
(Hs99999905_m1). We did not analyse for changes in expres-
sion of an unrelated gene to check for unintentional global
translational repression by interferon activation by siRNA treat-
ment. However, we did conﬁrm that the expression of the three
housekeeping genes, UBC, β actin and GAPDH, did not show a
signiﬁcant difference upon siRNA treatment of UCP2, by com-
paring each of the housekeeping genes with each other; that
is, comparing the UCP2 siRNA versus no treatment cells, there
was no signiﬁcant difference in GAPDH mRNA levels using UBC
as the housekeeping control, and similarly with other pairwise
comparisons. Each reaction was repeated three times in paral-
lel and for each condition. Crossing thresholds (Ct) were ob-
tained using relative quantiﬁcation application on the SDS2·1
software (Applied Biosystems, Life Technologies Ltd, Paisley,
UK). Any value that was not consistent with the rest of the trip-
licate was suppressed before analysis. As a positive control
using GAPDH siRNA, GAPDH mRNA was down-regulated by a
factor of 5.48 (P=0.001). The Ct values included in statistical
Table 2. Forward and reverse primers used during non-quantitative RT-PCR of human ACE, UCP3 and UCP2 and the housekeeping
gene GAPDH and the resulting amplicon size
Gene cDNA accession no. Primers Amplicon size, bp
hGAPDH J04038 F: GGGGAAGGTGAAGGTCGGAGT 228
R: CCTGGAAGATGGTGATGGGAT
hUCP3 U84763/AF050113 F: CCTCACTACCCGGATT 235
R: GTTGACGATAGCATTCCT
hUCP2 NM_003355/AF019409 F: GCTTTGAAGAACGGGAC 296
R: CTGTAACCGGACTTTAGCA
hACE J04144 F: ACCAATGACACGGAAAG 207
R: GTGGGTTTCGTTTCGG
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analysis were the means of triplicates. Experiments were
repeated between three and ﬁve times.
Statistical analysis
Allele frequencies were estimated by gene counting. A χ2 test
was used to compare the observed numbers of each genotype
with those expected for a population in Hardy–Weinberg
equilibrium. LD between sites in pairwise combination was esti-
mated [96]. One-way analysis of covariance (ANCOVA) tested for
confounders. Univariate and multivariate analyses were used to
measure signiﬁcance of association. Differences in descriptive
population variables and sACE were compared between geno-
type groups. For the whole sample, characteristics were com-
pared between genotype groups (including those deﬁned by
the presence/absence of a speciﬁc allele) using one-way
ANOVA, two-tailed unpaired t-tests, linear trend analysis and
one-way ANCOVA with sex as a covariate, using either raw or
log-transformed values as appropriate. Genotype association
with sACE activity in the HMAR study was compared between
genotype groups and allele groups using two-way ANOVA with
repeated measures on one factor (time). All data were analysed
using SPSS (SPSS Inc., IBM Corporation, USA) and Microsoft®
Ofﬁce Excel® 2007 (Microsoft Corporation 2006). Data are pre-
sented as means ± standard deviation unless otherwise stated.
P values of <0·05 were considered statistically signiﬁcant.
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